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Nutritional concerns in pediatric inflammatory 
bowel disease
Yong Joo Kim, MD, PhD
Department of Pediatrics, Hanyang University College of Medicine, Seoul, Korea
The pathophysiology and fundamental etiologic mechanism of inflammatory bowel disease (IBD) is 
not well understood even though therapeutic regimens and drugs are rapidly evolutionary. IBD has 
complicated connections with genetic, immunologic, gut microbial, environmental, and nutritional 
factors.  It is not clearly well known to the physicians how to feed, what nutrients are more helpful, and 
what food to be avoided. This review discusses the issues of growth and important nutritional concerns 
in the management of IBD in childhood.
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Introduction
All kinds of diseases may be related with what the people ingest. In Korea, most doctors 
had believed that inflammatory bowel disease (IBD) does not occur in this country for 
decades. However, the prevalence of IBD has jumped up during very short period as we 
have incurred quite westernized changes on our daily meal tables, although we cannot 
ignore that the evolution of the diagnostic approaches and the devices could have enabled 
the detection of IBD. 
The development of pharmacologic therapeutic regimens are already well known to 
the doctors, but they feel a scarcity of knowledge concerning how to teach and guide the 
patient toward good nutritional care and supplementation. Few physicians can detect what 
foods induces the patient be suffered by the aggravated symptoms and how to educate the 
parents to feed those children well. 
It was already required to let the physician be acknowledged about the nutritional 
therapy and care in the patients with IBD because these patients experience the relapse, 
aggravation, and serious delayed growth and pubertal development.
IBD and delayed growth and pubertal development
The main reasons why delayed linear growth is more common in IBD, especially Crohn 
disease (CD), are as follows; deficient meal intake due to fear of symptomatic aggravation, 
intestinal mucosal loss of nutrients, increased nutritional requirement and chronic catabolic 
status, pharmacologic treatment (corticosteroids) which can inhibit insulin-like growth 
factor-I (IGF-I), and disease activity producing cytokines which depress linear growth1).  
1. Cytokines
Retardation of growth and delayed pubertal development are one of the major nutri-
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tional issues in the children and adolescents with IBD, especially 
with CD. The main factors inducing these problems are poor 
nutritional conditions, the severity of the disease itself, genotype 
and the most important things; various cytokines tumor necrosis 
factor (TNF)-α, interleukin (IL)-6, IL-1β2). The presence of pro-
inflammatory cytokines, secreted from the inflammation sites, 
interferes linear growth of the patients. Among the numerous 
cytokines, TNF-α has a core role in the cytokine-associated 
growth retardation3-5). The effect upon growth is more aggressive 
as the severity of the disease itself is more fulminant and aggra-
vated. It is documented when we see treatment with anti-TNFα 
improves patient’s growth as well as clinical problems6).
This problem is more noticeable in the patients of CD. The pa-
tients with CD already show decreased growth velocity far before 
the diagnosis of CD, and become large burden to their parents 
and their doctors. 
2. Nutritional deficit
The symptoms of IBD between children and adults are all 
the same but the distinctive delayed growth. In the adults the 
growth is already completed and does not matter of linear 
growth, even though sometimes severe status accelerates weight 
loss. Contracting IBD before full growth let the patient have 
poor appetite due to gastrointestinal (GI) symptoms, avoid well-
eating and suffer from nutritional loss through the GI mucosa 
despite enough nutrient intake. So pediatric IBD patients show 
delayed growth. Furthermore, their developmental velocities 
are also retarded, and make them look younger than their peers. 
During active stage of CD, protein-losing enteropathy, mucosal 
hemorrhage, fistula, and hepatopathy result in hypoproteinemia. 
Chronic mucosal hemorrhage causes iron deficiency, and severe 
diarrhea induces electrolyte (potassium, magnesium) loss, and 
zinc deficiency, which in a cascade incur another GI problems of 
aggravated diarrhea, decreased immunity, and decreased tissue 
integrity7).  
Patients with IBD showed increased energy requirements and 
decreased energy expenditure, especially in the active status. With 
these reasons, 85% of CD patients, and 65% of ulcerative colitis 
(UC) already have weight loss at the time of initial diagnosis8). 
Those nutrient-associating problems in CD children may result 
in growth hormone (GH) resistance. They show decreased lean 
body mass with circulating IGF-I decrease9). Poor oral intake and 
malnutrition are related with acquired GH resistance at the site 
of GH receptor, and deficient serum nutrients conduct a GH-in-
dependent stimulatory effect on the height growth10).
3. Severity of disease
Even though their nutritional intake is enough, growth may be 
threatened by the disease severity, the loci of the active disease, 
pharmacologic agents. The usual activity index such as C-reactive 
protein (CRP) which reflects a short-term phenomenon does not 
give enough information concerning the severity itself in the 
chronic complicating diseases11). 
The severity of disease was documented to be the impactful 
indicator to predict retarded growth. The patients with higher 
pediatric CD’s disease activity index (PCDAI) score12) grow more 
slowly than those with lower score.
4. Pharmacologic agents
Corticosteroid therapy may be the direct cause of poor growth 
when it is used for long term. Glucocorticocoids directly inhibit 
the chondrocytes of bony growth plate. But short-term therapy 
is not directly related with growth retardation. The height of the 
patient is already low at the time of first diagnosis. And disease 
complications such as fistula also cannot be a reason of poor 
growth13).
In the large study of Griffiths et al14), the effect of corticosteroids 
on linear growth was weaker than the effect by disease severity, 
and they emphasized that major risk factor for growth retardation 
is disease severity.
These complicated problems of growth and development 
bother the patients even more than the clinical difficulties.
Nutrients and childhood IBD 
The eventual purposes of nutritional concern in the child-
ren with IBD are (1) improvement of nutritional status, (2) im-
provement of disease activity, (3) diminution of surgery indi-
ca tions and prevention of postoperative complications, (4) 
correction of pubertal growth retardation
The major purposes of the nutritional care are to alleviate the 
clinical conditions and to improve growth and development of the 
patients. In some patients, avoiding of dairy foods and fiber-rich 
foods diminish the GI symptoms. In some other patients, their GI 
symptoms become milder after decreasing fatty meals. Responses 
to dietary changes are different in the individuals des pite same 
diseases. Sometimes clinical dietician can be helpful to set up 
proper dietary plan for each patient. The patients experience 
which foods aggravate their symptoms and improve those. Most 
parents have wrong insight to some foods. Especially Ko rean 
traditionally have thought pork and chicken meal are not suitable 
for GI patients, but there is no evidence to support this claim.
Foods that aggravate the symptoms of acute stage of IBD are 
as follows; (1) grains such as soy, red bean, and sorghum, (2) 
uncooked vegetables and pickled veggie, (3) citrus fruits and 
juices, (4) spicy foods – hot, sour, salted, (5) fatty foods and 
trans fats especially in case of severe ileal disease, (6) sugar, (7) 
caffeinated foods, (8) dairy foods (milk fat, milk protein), and (9) 
meat and processed meats15,16).      
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Important nutritional concerns in pediatric IBD are (1) enteral 
nutrition (elemental nutrition), (2) total parenteral nutrition, (3) 
supplement of deficient nutrients-protein, vitamins (A, D, E, K, 
B12, folate), minerals (iron, zinc, calcium, phosphorus, magnesium, 
kalium), (4) avoidance of symptom-aggravating foods17-20).
Inflammation in the small intestine leads to poor digestion and 
absorption of food. As poorly digested food materials pass into 
the colon, diarrhea and loss of nutrient more progress. That is the 
reason why children with malnutrition and growth retardation are 
more common in CD than UC. The lesion site of UC is confined in 
the colon with normal mucosa of small intestine, so malnutrition 
is not severe as CD. But if the lesions are wider and more severe, 
diarrhea is more exaggerated as water is reabsorbed in the colon. 
Symptoms can be aggravated by some foods, but it does not 
indicate worsening disease severity. On the other hand, food 
poisoning or acute infectious gastroenteritis may aggravate the 
severity and affect the clinical course. Special dietary therapy is 
not required in IBD, we need to consider the diverse effects of 
specific foods.
1. Protein in IBD
The indirect index of protein-energy efficiency is kidney func-
tion, increase of body weight, biochemistry laboratory data, 
and acute phase reactant. Weight-for height explains the acute 
condition, while height-for-age suggests chronic status. Weight 
velocity and height velocity are very efficient indices for body 
growth. The indices which explain the quantitative status of pro-
tein are total protein, albumin, prealbumin, transferrin, retinol-
bind ing protein. The qualitative examinations to evaluate the 
disease activities of IBD are acute phase reactant proteins such as 
α1-, α2-macroglobulin, transferrin, CRP, complements, and ery-
throcyte sedimentation rate. 
Physicians need to measure weight, height, and monitor the 
above mentioned laboratory tests to assess the current disease 
activity and nutritional status.
2. Fat intake in IBD
The patient who suffers from IBD in the ileum or has undergone 
operation ileectomy requires low fat diet. Medium-chain trigly-
ceride is helpful for the patient with steatorrhea. Fish oil is also 
effective for the prevention of relapse. A research performed in 
high risk patients of CD showed that supplementation of enteric-
coated fish oil for one year prevented relapses in 59%, compared 
with 26% in the placebo group (P=0.003)21). The effect of fish oil 
on UC is still controversial22).
It is an important concern to know what oil is more helpful. 
High-fat meals rich in n-6 polyunsaturated fatty acids (PUFA) 
reportedly accelerate bacterial overgrowth but deplete microbes 
from Bacteroidetes and Firmicutes phyla. Fish oil supplementation 
(n-3 PUFA) recovered microbiota and inflammatory cell infil-
tration and accentuated regulatory T-cell recruitment. These 
findings suggest that n-6 PUFA-rich diet may induce dysbiosis 
and gut inflammation in aged mice, while fish oil supplementation 
together with an n-6 PUFA diet can down-regulate dysbiosis23,24).
Trans fatty acids (TFA), known as major causes of metabolic 
syndrome, negatively affect IBD development and aggravation. 
Cytokine expression from the lesion sites is higher in lipopolysac-
charide-stimulated cells exposed to TFA. It exacerbates colonic 
inflammation by inducing Th17 polarization and by up-regu lating 
the pro-inflammatory cytokines from the affected mucosa25,26). 
Accordingly, patients with IBD should avoid TFA-containing 
foods such as fried and instant foods.
3. Micronutrients and minerals in IBD
IBD patients are prone to be deficient in water-soluble vitamins 
as well as lipid-soluble vitamins. They are on low-fiber, low-resi-
due diet during active stage. In that case water-soluble vitamins 
are deficient. If the lesion is within the ileum, a vitamin B12 defi-
ciency follows. After small intestine surgery or if a small intestinal 
lesion is severe, vitamin D, calcium, magnesium, phosphorus, and 
iron are more likely to become deficient.
Micronutrient deficiency are caused by insufficient intake due 
to the disease itself, acute or chronic GI mucosal loss, and as a side 
effect of some drugs. Sulfasalazine (SSZ) inhibits the absorption 
of folate, corticosteroids suppress the absorption of calcium, and 
cholestyramine interrupt the absorption of lipids and lipid-soluble 
vitamins.  
As such, physicians recommend the use of elemental formula 
rather than a general diet to patients with severe disease or acute-
onset status.
Folate is absorbed in the small intestine and stored in the liver. 
The storage period is several months, so folate-rich food intake 
is recommended. Patients with small intestine diseases are prone 
to folate deficiency, which may also be induced by drugs as SSZ 
and methotrexate (MTX). SSZ is a potent inhibitor of reduced 
folate carrier, the dominant cell membrane transporter for natural 
folate27). MTX is predominantly in its polyglutamated form with 
scarce of hepatic folate storage28). Folate is important in human 
body because it synthesizes DNA, repairs DNA, methylates DNA , 
and acts as a cofactor in certain biological reactions; accordingly, 
it prevents the development of colon cancer in patients with UC29). 
Daily requirement of folate in normal adult is 50 μg per day, while 
patients with IBD require 6-8 times that amount.
Vitamin B12 is synthesized in the ileum. Deficiencies occur in 
approximately 20% of patients with CD30). If the lesion is in the 
ileum or the patient underwent ileectomy, deficiency is more 
likely to occur. Periodic intramuscular injections are required if the 
patient is too severely affected to acquire sufficient nutrition via 
oral intake31).  
Vitamin B6 may become deficient in patients with CD, followed 
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by deficiencies of vitamin B1, vitamin B2, and pantothenic acid.
 Vitamin C deficiency is common in IBD. Vitamin C is a strong 
antioxidant. During the initial severe clinical stage, patients are 
recommended to follow low-residue diet and eat fewer vegetables 
and fruits, making them prone to vitamin C deficiency. Vitamin 
C protects intestinal mucosa from inflammation. Vitamin C 
deficiency is suspicious in patients with ano-enteral fistula32).
Vitamin A deficiency is uncommon, but may occur if the lesion 
site is within the small intestine. Vitamin A deficiency leads to 
impairment of night vision. Beta carotene, precursor of vitamin A 
is a representative antioxidant. 
Vitamin D deficiency is common in patients with CD. Poor 
absorption of lipids, deficiency of bile juice, and ileal surgery in 
patients with CD even more cause the deficiency. In this case, 
growth retardation and osteoporosis are noticed especially in 
CD rather than UC. Bone fractures sometimes occur in pediatric 
patients with CD treated with corticosteroid therapy33).
Vitamin E also may be deficient in patients with IBD, which 
delays healing of the mucosal lesions.
Vitamin K, which is produced in the small intestine, is com-
monly deficient in patients with CD as well as those with UC. 
The major causes of this deficiency are impaired absorption and 
antibiotic therapy34).
Zinc deficiency, caused by poor absorption or hypoalbuminemia 
is sometimes recognized in patients with CD. This deficiency is 
responsible for some disease manifestations such as malaise, 
poor wound healing and rashes inducing anorexia, decreased GI 
absorption or increased GI loss35). A research report showed that 
there is a correlation between zinc and vitamin A and the disease 
activity score (PCDAI), and a weaker correlation with serum pro-
teins to this score. No correlation was found with vitamin B12 
absorption, disease localization, or previous ileal resection36).
Calcium supplementation is required as well. Deficiency is 
caused by not only decreased dietary intake but also hypoalbu-
minemia induced by the disease itself or medication like MTX. 
Calcium deficiency is not apparent at the early stage of diagnosis, 
but as the disease progress, the deficiency can develop. Vitamin D 
enhances calcium absorption in the intestine, so the intake of these 
two nutrients is helpful. The daily requirements for patients with 
IBD are 1,200 mg of calcium, and 1,000 IU of vitamin D, which 
are beyond the daily requirements of average normal adults37).
Magnesium may also be deficient, symptoms of which include 
muscle spasm and bone pain. In IBD, magnesium deficiency is 
caused by small intestine surgery, malabsorption, and mucosal 
loss.
4. Micronutrient to be alert
Iron deficiency, the most common micronutrient deficiency 
in patients with IBD, caused by mucosal hemorrhage, anorexia, 
and malabsorption. A recent study showed that the oral supple-
mentation of iron increases oxidative stress and aggravates the 
mucosal inflammation38). Iron deficiency prevents CD-like ileitis 
by altering the gut microbiota39). As such, supplementation via 
intravenous route with decreased oral dose amount is desirable in 
the very acute stage.
Choline and carnitine, which are sufficient in red meat and 
eggs, comprise major components of cell membrane and have a 
pivotal role in synthesizing very low density cholesterol in the 
liver. If their levels become depleted in an obese person, fatty 
liver disease can easily develop40). In a patient of acute ulcerative 
colitis the intraepithelial choline level is lower than that of re-
mission state patients41). However, it is still to be determined 
whether choline deficiency plays a role in the development of 
experimental colitis and human IBD. It is believed that red meat 
can alter or aggravate ulcerative colitis. Until now there is no 
evidence to resist this opinion. Intestinal microbial choline meta-
bolism may be linked with IBD. Germ-free mice do not produce 
increased timethylamine-N-oxide (TMA) when on a high-
choline diet. Interestingly, IBD patients are tend to be at increased 
risk of cardiovascular disease. Recent study showed that IBD is 
associated with increased levels of urinary TMA, which is indi-
cative of enhanced choline metabolism and decreased choline 
bio-availability42). So these patients are recommended to be 
monitor their intake of this nutrient.  
Conclusions
There is still specific food of choice to treat IBD. However, it 
would be very helpful and efficient if physicians encourage pa-
tients with IBD to limit foods that may aggravate the disease. 
With sufficient information about nutritional issues in addition to 
traditional treatments, clinicians can promote improved growth 
and quality of life in children with IBD.
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